How Bristol-Myers Squibb (BMY) Makes Money: A Visual Guide
Bristol-Myers Squibb (BMY) generated $48.19B in revenue (TTM through Q4 2025), earning $7.05B in net profit (14.6% margin). Its largest revenue source is Eliquis (30% of revenue). Below is an interactive breakdown of how revenue flows through the income statement.
Bristol-Myers Squibb (BMY) Income Statement Flow
Frequently asked questions
How does Bristol-Myers Squibb (BMY) make money?
- Bristol-Myers Squibb (BMY) primarily makes money through Eliquis, which accounts for 30% of total revenue. For TTM through Q4 2025, Bristol-Myers Squibb generated $48.19B in total revenue with a net profit margin of 14.6%.
What is Bristol-Myers Squibb (BMY) gross profit margin?
- Bristol-Myers Squibb (BMY) reported a gross profit margin of 67.6% for TTM through Q4 2025, equivalent to $32.60B in gross profit. This means Bristol-Myers Squibb retains 67.6% of each revenue unit after direct costs of production.
What is Bristol-Myers Squibb (BMY) operating profit margin?
- Bristol-Myers Squibb (BMY) reported an operating profit margin of 26.3% for TTM through Q4 2025, equivalent to $12.70B in operating profit. This reflects profitability after operating expenses such as R&D, sales, and administration, but before taxes and non-operating items.
What is Bristol-Myers Squibb (BMY) net profit margin?
- Bristol-Myers Squibb (BMY) reported a net profit margin of 14.6% for TTM through Q4 2025, equivalent to $7.05B in net profit. This is the share of revenue that remains as profit after all expenses, taxes, and non-operating items.
How much does Bristol-Myers Squibb (BMY) invest in R&D?
- Bristol-Myers Squibb (BMY) invested $9.61B in research and development in TTM through Q4 2025 (19.9% of total revenue). R&D spending reflects investment in future products, services, and technologies.
How much does Bristol-Myers Squibb (BMY) spend on capital expenditures?
- Bristol-Myers Squibb (BMY) spent $1.31B on capital expenditures in TTM through Q4 2025 (2.7% of total revenue). Capital expenditures represent investments in physical assets such as property, equipment, and infrastructure.
What is Bristol-Myers Squibb (BMY) free cash flow?
- Bristol-Myers Squibb (BMY) generated $12.85B in free cash flow for TTM through Q4 2025 (26.7% of total revenue). Free cash flow is the cash remaining after capital expenditures and represents the company's ability to fund growth, pay dividends, or reduce debt.
What is Bristol-Myers Squibb (BMY) effective tax rate?
- Bristol-Myers Squibb (BMY) had an effective tax rate of 24.4% for TTM through Q4 2025. This is the actual percentage of pre-tax income paid as income taxes.
About this data
- What is a Sankey diagram?
- A Sankey diagram shows how money flows through a company from revenue to net profit. The width of each flow represents its proportion.
- How is the data calculated?
- We use the income statement from company filings. For TTM (Trailing Twelve Months), we sum the last four quarters. Revenue flows to cost of revenue and gross profit, then to operating expenses (R&D, S&M, G&A) and operating profit.
- When was this data last updated?
- Based on company filings through TTM through Q4 2025.